摘要
目的探讨丽珠肠乐联合曲美布汀治疗肠易激综合征的临床疗效及不良反应。方法将116例临床诊断的肠易激综合症患者随机分成丽珠肠乐联合曲美布汀组(A组,n=40)、丽珠肠乐组(B组,n=38)和曲美布汀组(C组,n=38),A组给予丽珠肠乐口服1次2粒,早晚各1次餐后口服,曲美布汀口服每次0.1 g,每日3次;B组和C组则单独口服以上二药治疗,4周为一疗程。三组分别于治疗前、治疗4周后观察临床症状及不良反应。结果治疗4周后,A、B、C三组临床总有效率分别为92.5%,71.1%和78.9%,三组比较差异有显著性(P<0.05),三组均未见明显不良反应。结论丽珠肠乐联合曲美布汀治疗肠易激综合征比单用丽珠肠乐或曲美布汀具有更好的疗效。
Objective To investigate the clinical effect of live bifidobacterium capsules combined with trimebutine maleate capsules for the irritable bowel syndrome. Methods 116 patients with clinically proved the irritable bowel syndrome were randomly divided into three groups: Live Bifidobacterium Capsules combined with Tfimebutine Maleate Capsules group ( group A, n = 40 ) , Live Bifidobacterium Capsules group ( group B, n = 38 ) and Trimebutine Maleate Capsules group ( group C,n = 38). Three groups are treated with different therapies: for the group A, Live Bifidobacterium Capsules 2 cap, twice a day, combined with Trimebutine Maleate Capsules 0.1 g twice a day ; while for the group B monothcrapy with Trimebutine Mal- eate Capsules 0.1 g twice a day and group C monotherapy with Trimebutinc Maleate Capsules 0.1 g twice a day. The course of treatment was 4 weeks. To reexamine and clinical symptomy were monitored in all patients after 4 weeks treatment. Results After 4 weeks treatment,the clinic effective rate in group A,B and C were 92.5% ,71.1% and 78.9% ,The difference of the efficacy between the three groups are significant statistically ( P 〈 0.05 ). Conclusion The efficacy of mutitherapy of live bifidobacterium capsules combined with trimebutine maleate capsules on irritable bowel syndrome was better than that of monotherapy of live bifidobacterium capsules o1" mosapride.
出处
《中国医学创新》
CAS
2010年第14期3-5,共3页
Medical Innovation of China
关键词
丽珠肠乐
曲美布汀
肠易激综合征
Live bifidobacterium capsules
Trimebutine maleate capsules
Irritable bowel syndrome